Board Chair

Alan Goldhammer, PhD

Dr. Goldhammer is an independent consultant in drug regulatory affairs. He received his BA in chemistry from UC Santa Barbara and his PhD in biological chemistry from Indiana University.  He held an NIH post-doctoral fellowship at Cornell University and was a Senior Staff Fellow in the Clinical Endocrinology Branch, NIDDK. Dr. Goldhammer spent 27 years in the biopharmaceutical industry in regulatory affairs and drug safety, retiring in 2010 as the Vice President for Scientific and Regulatory Affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA).  While at PhRMA, Dr. Goldhammer coordinated several projects that led to public/private partnerships between the FDA, NIH, and the pharmaceutical industry and also received two awards for exceptional service.  Dr. Goldhammer has served on advisory panels for the Institute of Medicine, the Office of Technology Assessment, the Food and Drug Administration, and the Environmental Protection Agency.  Dr. Goldhammer currently assists industry and academic clients on matters of drug development and drug safety. He also chairs the FAES Investment Committee.

1st Vice Chair

Kathryn Norcross, JD

Retired Chief, Appellate Litigation Unit, Legal Division, FDIC

Ms. Norcross is a lawyer with more than 40 years of experience in private practice and the federal government. Ms. Norcross served the Federal Deposit Insurance Corporation in its Legal Division for 33 years, retiring from the role of Chief, Appellate Litigation Unit. At the FDIC, she supervised lawyers who briefed and argued appeals pending in federal and state courts across the country involving directors’ and officers’ liability, federal tax, commercial, bankruptcy, banking, employment and administrative law issues. Before that, she supervised lawyers in FDIC’s Commercial Litigation Unit who represented the FDIC at the trial level in cases that arose in the wake of the 2008 financial crisis. She has been involved in some of the largest bank failures in the nation’s history, including as FDIC’s chief negotiator for the settlement of large lawsuits arising out of the failure of Washington Mutual Bank. Ms. Norcross also taught Appellate Advocacy at American University’s Washington College of Law, where she received the Adjunct Professor of the Year Award for Excellence in Teaching. She is admitted to practice before the U.S. Supreme Court, and holds licenses to practice law in Maryland, DC, Texas and NJ. She has filed briefs or appeared before every Federal Circuit Court, numerous Federal District Courts, and many state courts.

2nd Vice Chair

Vacant

Treasurer

Nancy Johnson, CPA

Partner, UHY LPP

Ms. Johnson is a partner at UHY LLP, specializing in audit and assurance services to not-for-profit organizations and qualified employee benefit plans. She received her BS in Accounting from Auburn University and is a licensed CPA in the state of Maryland and in Washington, D.C. She has more than 30 years of experience in not-for-profit assurance, specializing in trade associations, charities, membership organizations, and educational institutions. Ms. Johnson conducts financial audits, reviews, and compilations. Her specific experience with not-for-profit entities includes financial audits plus audits in accordance with Government Auditing Standards and Single Audits under OMB Uniform Guidance and Presentations to Audit Committees and Boards of Directors. Ms. Johnson is a member of the American Institute of Certified Public Accountants Maryland Association of Certified Public Accountants.

Secretary

Joshua Farber, MD

Chief, Inflammation Biology Section, NIAID

Dr. Farber* is Senior Investigator and Chief, Inflammation Biology Section, Laboratory of Molecular Immunology at the National Institute of Allergy and Infectious Diseases. He received his MD from Johns Hopkins University in 1977 and completed his residency in internal medicine and fellowship in infectious diseases at Hopkins. He pursued research training in the Laboratory of Biochemistry, NHLBI (Earl Stadtman laboratory) and in the Department of Molecular Biology and Genetics at Hopkins (Daniel Nathan laboratory). He joined NIH as an Investigator in the Laboratory of Clinical Investigation in 1993 and became Senior Investigator in 2000. He is an elected member of the American Association of Physicians. 

*Dr. Farber is serving in a personal capacity as an outside activity.

Samuel Buckner, BA

Mr. Buckner is Founding Member and Managing Partner, Brokerage and Advisor Services at The Tenant Agency. Mr. Buckner is a graduate of the University of Maryland, and a licensed real estate broker in the District of Columbia, Maryland, and Virginia.  He spent the first 10 years of his career with a global real estate firm in Washington, DC.  He now specializes in working with nonprofit organizations, professional services companies, trade associations, and high growth technology companies in the DC region to identify opportunities for taking advantage of real estate market conditions. Mr. Buckner is an expert in reducing costs and increasing flexibility for clients, creating work environments that promote productivity, innovation, and collaboration in a cost-effective manner.  Past and current clients include the FNIH, the National Association of Community Health Centers, the National Park Foundation, the American Telemedicine Association, the Society of Developmental Biology, and the American Society for Pharmacology and Experimental Therapeutics.

Jennifer Catalano, MBA, PhD

International Trade Analyst, US International Trade Commission

Dr. Catalano is an International Trade Analyst with the U.S. International Trade Commission. She received her BS in chemistry and BA in English from the University of Rochester, her MBA in international business from the Georgetown University McDonough School of Business, and her PhD in pharmacology and experimental therapeutics from the University of Maryland.  She completed the FAES Advanced Studies in Technology Transfer program and has contributed to that FAES curriculum as an instructor and lecturer.  Dr. Catalano is accountable for analysis on subjects such as trade valuation, supply chain integration, economic modeling assistance, trade and investment policies, and visits to factories to evaluate manufacturing sites. She was appointed as liaison between her agency and the Office of the President, U.S. Trade Representative (USTR) for a one-year term on technical matters. She provides contribution analysis and advice to the USTR that has use in negotiations at the World Trade Organization. Dr. Catalano works with a team of attorneys, economists, and accountants who analyze information for international disputes and produce informative publications for Congress and the public. She previously held the positions of chemist and biologist at the FDA for 10 years, working for six of those years as the FDA representative to the International Conference on Harmonization acting as a negotiator and diplomatic leader to create innovative standards to be integrated into management processes for numerous countries. At the FDA she was chair for the large-scale data group at her Center, and she led her group towards a successful working solution to integrate novel technology containing unprecedented large-scale data into new management practices.

Michael Collins

Michael Collins, MD, recently retired Chief, Skeletal Disorders and Mineral Homeostasis Secon, National Institute of Dental and Craniofacial Research, NIH, where he spent a 29-year career studying bone biology and mineral metabolism, focusing on disorders such as fibrous dysplasia of bone, hypoparathyroidism, and diseases of FGF23 excess and deficiency. He started his studies as a classical musician, obtaining a music degree in clarinet performance from Catholic University, before switching to medicine and obtaining his medical degree from the University of Maryland, where he also completed his residency and chief residency in internal medicine. Dr Collins did his endocrine fellowship at the NIH, and remained there for his entire career. He made major contribuons to understanding the pathophysiology and natural history of McCune-Albright Syndrome/Fibrous Dysplasia and has served as the Chair of both the Medical and Science Advisory Boards of the Fibrous Dysplasia Foundation. He was also a member of the FDA Advisory Committee for Reproductive Drugs. Dr Collins trained a large number of clinical and research fellows and post-bacc scholars, and was the recipient of numerous NIH awards, including the NIDCR 2022 Mentoring Award. FAES Activities: For more than a decade, Dr Collins has been an instructor in the FAES Endocrine Board Review Course, giving lectures on osteoporosis and other bone disorders. He is interested in advising FAES Academic Programs about Workshop collaborations, and joining the FAES Music Committee. As a former resident of the Alta Vista neighborhood in Bethesda, he would also like to participate in the FAES Real Estate Working Group.

Mitchell Ho, PhD

Deputy Chief, Laboratory of Molecular Biology, Director of Antibody Engineering Program, NCI

Dr. Ho * is Deputy Chief, Laboratory of Molecular Biology, National Cancer Institute and Director of the NCI Antibody Engineering Program. He received a BS from East China Normal University and an MA from San Francisco State University. He received his PhD at the University of Illinois at Urbana-Champaign, and completed a postdoctoral fellowship with Ira Pastan at the NCI. Dr. Ho became a Tenure Track Investigator at the NCI in 2008 and was promoted to Senior Investigator in 2015. His laboratory studies the molecular basis of cell surface receptors and designs novel antibody therapeutics. The antibodies, CAR T cells, and immunotoxins developed in his lab are being tested at preclinical and clinical stages for liver cancer, neuroblastoma, mesothelioma, and pancreatic cancer. 

*Dr. Ho is serving in a personal capacity as an outside activity.

Robert Hohman, PhD

Retired Chief, Research Technologies Branch, NIAID, NIH

Dr. Hohman retired from the NIH in 2019, and currently provides technology consulting to government, industry, and academic institutions. He received his PhD in Microbiology from the University of Maryland and the NIH, where his PhD advisor was Dr. Earl Stadtman at NHLBI. After a postdoctoral position in the Laboratory of Biochemistry at the Pasteur Institute in Paris, he returned to the NIH for a second postdoctoral appointment during which he studied IgE receptor-mediated activation of mast cells. In 1992, Dr. Hohman joined Oncor Inc, a biotechnology company that specialized in DNA diagnostics based on fluorescence in situ hybridization (FISH). He became Vice President of Research and Development and helped Oncor produce the first FDA-approved FISH-based DNA diagnostic test, HER-2/neu, for women with breast cancer. While at Oncor, Dr. Hohman established a research products division; in 1998, this division was sold to Intergen and he became Vice President for Research and Development of the newly formed Intergen Discovery Products. In 2000, Dr. Hohman was recruited back to NIH to become Chief of the Research Technologies Branch (RTB) at NIAID. The RTB is a $15 million program that provides state-of-the-art technologies to the Division’s 120 principal investigators and 500 postdoctoral and clinical fellows. Dr. Hohman managed a staff of 60 scientists who developed technologies in the fields of flow cytometry, confocal and electron microscopy, structural biology, genomics, and bioinformatics.

Marita Hopmann, PhD

Dr. Hopmann received her PhD from University of Minnesota, 1984, Institute of Child Development. Dr. Hopmann was a faculty member in the Psychology Department of Macalester College, St. Paul, MN, where she supervised honors theses, chaired the college’s Curriculum Department, founded and chaired the college’s IRB, and co-founded the Junior Faculty Caucus, a group of untenured faculty who met regularly to discuss professional development issues. In 1985, Dr. Hopmann joined the Pediatrics Department at Brown University’s School of Medicine as an Assistant Professor (Clinical) at the Child Development Center. She founded a research program in Language and Communication Disabilities, focusing on children with Down syndrome. She was a member of Rhode Island Hospital’s IRB for seven years. Dr. Hopmann worked at the NIH as a Scientific Review Administrator and Associate Director for Staff Development and Training for the Scientific Review Branch at NICHD for 17 years until her retirement in 2017. She assembled and ran the first Biobehavioral and Behavioral Sciences Subcommittee for NICHD, and administered reviews of behavioral developmental science of individual-initiated grant and career development applications and program projects. She co-founded SPRIG (Scientific Program and Review Interest Group), the first intramural/extramural NIH interest group, reflecting her interest in improving NIH science management and the quality and enjoyment of work at NIH. She conducted workshops on the NIH grant application process at international and national conferences in pediatrics and developmental psychology. Dr. Hopmann had three years of prior experience in federal administration as a research fellow in the Office of Research and Evaluation for the Administration on Children, Youth, and Families (ACYF). She administered the Quality Research Centers (QRCs) for the Head Start Bureau, and supervised the Head Start Research Scholars program, two-year grants for PhD candidates doing research with children in Head Start programs.

John “Ted” Ibex, CPA, ABV, CFF, MBA

Forensic Accounting Practice Professor of Accounting and Auditing

Mr. Ibex is a semi-retired certified public accountant (CPA) with a forensic accounting and investigations practice. He is a professor of accounting and auditing. He received his BS and MBA in Accounting from Penn State University. Mr. Ibex was partner in a forensic accounting firm formed in 1987 through 2010, which began as Winters & Ibex, CPAs, merged into Rosenfarb & Winters, CPAs, and merged again in Marcum, LLP. Prior to self-employment, Mr. Ibex worked for United States Army office 1967 – 1969 (active service), began his career as an auditor with Arthur Andersen & Co. (1965-1980), and was chief financial officer for two corporations. Mr. Ibex has served in many organizations in a volunteer and elected capacity as a Rotarian, elected to Board of Education (17 years of service), elected to town council (7 years of service), treasurer of Rotary Foundation Asbury Park [NJ], and Cancer Support Community. He is Chair of the FAES Audit Oversight Committee.

Dennis Klinman, MD, PhD

Chief Scientific Officer, COBRO Ventures, Inc

Dr. Klinman is Chief Scientific Officer at Cobro Ventures. He obtained his MD and PhD in Immunology from the University of Pennsylvania, and completed his fellowship training in rheumatology at National Institute of Arthritis and Musculoskeletal and Skin Diseases, where his research focused on understanding the molecular and cellular basis of autoimmune disorders. He joined the FDA Center for Biologics Evaluation and Research (CBER), earned tenure, and was promoted to Senior Investigator and Captain in the Public Health Service (PHS). In 2007, he transferred to the National Cancer Institute as Chief of the Immune Modulation Section in the Cancer and Inflammation Program, where his lab developed methods to improve anti-cancer immunity in the tumor microenvironment. He is the holder of numerous patents related to use of immunomodulatory CpG oligonucleotides. Dr. Klinman is the recipient of Outstanding Service, Meritorious Service, and Distinguished Service medals from the PHS, two Technology Transfer awards from the NIH, a Mentor of Merit award from the NCI, and is a member of the governing board of the International Society of Vaccinology. He retired from the NIH in 2019 and is currently the CSO for a private investment firm focused on software and biotech.

Henry Levin, PhD

Chief Section on Eukaryotic Transposable Elements, NIH/NICHD

Dr. Levin* is Chief, Section on Eukaryotic Transposable Elements, National Institute of Child Health and Human Development. He received his BA in Chemistry from Oberlin College and his PhD in Molecular Biology at the University of California, Berkeley. He did a postdoctoral fellowship at the Johns Hopkins University Medical School and in 1992 joined the intramural program at NIH as a tenure track investigator in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). He served on several committees including the NICHD tenure and promotions committee and the NIH Central Tenure Committee. 

*Dr. Levin is serving in a personal capacity as an outside activity.

Gerald McLaughlin, PhD

Deputy Chief, NIDA OEPR

Dr. McLaughlin* is Deputy Chief, National Institute on Drug Abuse Office of Extramural Policy and Review. He received his AB in biochemistry from UC Berkeley and his PhD in molecular symbiology/physiology from the University of Iowa, and after NIH, NSF, and NRC postdocs at Notre Dame, Texas A&M Medical School, and the CDC, was a professor at the University of Illinois at Urbana-Champaign, Purdue University, and the Indiana University (IU) School of Medicine. His research was funded continuously for 22 years by grants and contracts from NIH, NSF, AID, and WHO. He was co-editor for BioPlatform and SmallCapsOnline biotechnology analysis groups, co-developed several marketed clinical diagnostic products, and was director of the molecular diagnostics, microbiology, and parasitology clinical laboratories and deputy director for the IU Health University Hospital’s clinical diagnostic laboratories. His research advanced molecular phylogeny with an emphasis on evolution, diagnostics, and drug development, and included research on malaria, pneumonia, and viral infections including AIDS. He joined NIAID in 2000 as a Scientific Review Officer, and in 2005 moved to NIDA as chief of the Scientific Review Branch, and in 2020 to Deputy. He contributed to several trans-NIH and NIDA workgroups and committees, notably eSubmission, Appendix, NIH Review Users Group and Review Policy Committee, and worklife, genetics/epigenetics, AIDS, and Neuroscience workgroups. He co-manages the NIH Mitochondria Interest Group (2000-) and co-managed the NIH Biocomputing Interest Group (2005-2016). 

*Dr. McLaughlin is serving in a personal capacity as an outside activity.

Yosuke Mukoyama, PhD

Senior Investigator, Laboratory of Stem Cell and Neuro-Vascular Biology, NHLBI, NIH

Dr. Mukoyama* is Senior Investigator, Laboratory of Stem Cell and Neuro-Vascular Biology, National Heart Lung and Blood Institute. He obtained his PhD in Developmental Biology from the University of Tokyo, Japan. He did postdoctoral research in the laboratory of Dr. David Anderson at the California Institute of Technology. He joined the NHLBI as a tenure-track investigator, and has been a Senior Investigator since 2014. Research in his laboratory is aimed at understanding fundamental mechanisms in the branching morphogenesis and patterning of the nervous system and vascular system at the single-cell level using high-resolution whole-mount imaging and genetic tools. 

*Dr. Mukoyama is serving in a personal capacity as an outside activity.

Philip Murphy, MD

Chief Laboratory of Molecular Immunology, NIAID, NIH

Dr. Murphy* is Chief, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases. He obtained his AB in Biochemistry from Princeton and his MD from Cornell. He completed his residency and served as a chief resident in Internal Medicine at NYU-Bellevue Medical Center before coming to NIAID as a Clinical Fellow in Infectious Diseases. He was promoted to Senior Investigator in NIAID in 1992, and in 2003 became the founding Chief of a new NIAID lab, the Laboratory of Molecular Immunology. Dr. Murphy's research focuses on basic, translational, and clinical studies related to G protein-coupled chemotactic receptors of the immune system. Recently, his research focus expanded to include basic and clinical studies of WHIM syndrome, a primary immunodeficiency disease caused by mutations in CXCR4. He has published 321 papers in immunology, two of which have been selected as Classics by Science Magazine, and he has been elected to the American Society for Clinical Investigation, the Association of American Physicians and the Henry Kunkel Society. 

*Dr. Murphy is serving in a personal capacity as an outside activity.

Allison C Nugent, PhD, Director, (MEG) Core Facility, NIMH, NIH

PhD, Director, Magnetoencephalography (MEG) Core Facility, NIMH, NIH

Dr. Nugent received her BS in physics and math from Missouri State University, a PhD in physics from Duke University, and an MA in bioethics from the Medical College of Wisconsin. Dr. Nugent came to the NIH in 2001 as a staff scientist under Dr. Wayne Drevets in NIMH, where she supported a neuroimaging program including MRI and PET studies. In 2009 she began working under Dr. Carlos Zarate, also of NIMH, where she directed a neuroimaging program including MRI, PET, and MEG studies. 
In 2018, Dr. Nugent began her tenure as the director of the NIMH MEG Core Facility. Her research focuses on novel applications of MEG and development of optically pumped magnetometer arrays for high resolution MEG.  
Dr. Nugent serves as Secretary of the NIH Assembly of Scientists and has served on the NIH Anti-Harassment Steering Committee since its inception. She is committed to the training mission of the NIH. Dr. Nugent has mentored or co-mentored post-baccalaureate, pre-doctoral, and post-doctoral fellows nearly every year of her 20-year tenure at the NIH. She has also been involved directly in organized training programs. She has assisted with the NIMH Ethics for Lunch ethics training program, has served as a guest lecturer for the FAES Neurobiology of Mental Illness course, and currently oversees formal training for users of the MEG Core Facility. Dr. Nugent also recognizes and appreciates FAES’s unique services to NIH. Her lab has benefited directly from the educational courses offered, financial and logistical support of NIH sponsored workshops, and the insurance program for trainees.

Susan Wright, PhD

Program Director, Big Data and Computational Science, Division of Neuroscience and Behavior, NIDA

Dr. Wright* is Program Director, Big Data and Computational Science, Division of Neuroscience and Behavior at National Institute of Drug Abuse, where she oversees the program that advances NIDA’s Strategic Plan for Data Science. Having trained in both neuroscience and computer science, Dr. Wright envisions how big data science can be used to understand the biological underpinnings of disease, and she is committed to promoting opportunities for cutting edge computational capabilities to be combined with biomedical research. Her portfolio includes data curation, sharing, access, reproducibility, security, analysis, harmonization, quality metrics and standards, and visualization. She serves on many NIDA, NIH-wide and multi-agency committees, including the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) initiative, the Helping End Addiction Long-term (HEAL) initiative, the Science and Technology Research Infrastructure for Discovery, Experimentation, and Sustainability (STRIDES) initiative, and the Collaborative Research in Computational Neuroscience (CRCNS) program. She works closely with the Office of Data Science Strategy on implementation of the NIH Strategic Plan for Data Science. 

*Dr. Wright is serving in a personal capacity as an outside activity.